Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
2000-12-4
pubmed:abstractText
Patients with schizophrenia show impairments of attention and neuropsychological performance, but the extent to which this is attributable to antipsychotic medication remains largely unexplored. We describe here the putative influence of the dose of antipsychotic medication (chlorpromazine equivalents, CPZ), the antipsychotic serum concentration of dopamine (DA) D2-blocking activity and the approximated central dopamine D2-receptor occupancy (DA D2-occupancy), on conditioned blocking (CB) measures of attention and performance on a neuropsychological battery, in 108 patients with schizophrenia (compared with 62 healthy controls). Antipsychotic serum concentration and D2-occupancy were higher in patients with a paranoid versus non-paranoid diagnosis, and in female versus male patients (independent of symptom severity). Controlling for D2-occupancy removed the difference between high CB in paranoid and impaired low CB in non-paranoid patients. Similar partial correlations for antipsychotic drug dose and serum levels of DA D2-blocking activity with performance of the trail-making and picture completion tests (negative) and the block-design task (positive) showed the functional importance of DA-related activity. High estimates of central DA D2-occupancy were related to impaired verbal fluency but were associated with improved recall of stories, especially in paranoid patients. This, the first study of its kind, tentatively imputes a role for DA D2-related activity in left frontal (e.g. CB, verbal fluency) and temporal lobe functions (verbal recall) as well as in some non-verbal abilities mediated more in the right hemisphere in patients with schizophrenia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0955-8810
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
317-30
pubmed:dateRevised
2009-7-7
pubmed:meshHeading
pubmed-meshheading:11103886-Adult, pubmed-meshheading:11103886-Antipsychotic Agents, pubmed-meshheading:11103886-Attention, pubmed-meshheading:11103886-Case-Control Studies, pubmed-meshheading:11103886-Chlorpromazine, pubmed-meshheading:11103886-Cognition Disorders, pubmed-meshheading:11103886-Conditioning, Classical, pubmed-meshheading:11103886-Dose-Response Relationship, Drug, pubmed-meshheading:11103886-Female, pubmed-meshheading:11103886-Frontal Lobe, pubmed-meshheading:11103886-Humans, pubmed-meshheading:11103886-Male, pubmed-meshheading:11103886-Mental Recall, pubmed-meshheading:11103886-Paranoid Disorders, pubmed-meshheading:11103886-Receptors, Dopamine D2, pubmed-meshheading:11103886-Schizophrenia, pubmed-meshheading:11103886-Sex Factors, pubmed-meshheading:11103886-Trail Making Test, pubmed-meshheading:11103886-Verbal Behavior
pubmed:year
2000
pubmed:articleTitle
Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy.
pubmed:affiliation
University Clinic for Child and Adolescent Psychiatry and Psychotherapy, Essen, Germany. oades@uni-essen.de
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't